These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Evaluating the safety and efficacy of felbamate in the context of a black box warning: A single center experience. Shah YD; Singh K; Friedman D; Devinsky O; Kothare SV Epilepsy Behav; 2016 Mar; 56():50-3. PubMed ID: 26828692 [TBL] [Abstract][Full Text] [Related]
14. Felbamate therapy in the Lennox-Gastaut syndrome. Snodgrass SR N Engl J Med; 1993 Jun; 328(22):1641. PubMed ID: 8487814 [No Abstract] [Full Text] [Related]
15. Felbamate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy. Palmer KJ; McTavish D Drugs; 1993 Jun; 45(6):1041-1065. PubMed ID: 7691493 [TBL] [Abstract][Full Text] [Related]
19. Felbamate in therapy-resistant epilepsy: an Italian experience. Felbamate Italian Study Group. Avanzini G; Canger R; Dalla Bernardina B; Vigevano F Epilepsy Res; 1996 Nov; 25(3):249-55. PubMed ID: 8956923 [TBL] [Abstract][Full Text] [Related]
20. The rise and fall of felbamate as a treatment for partial epilepsy--aplastic anemia and hepatic failure to blame? Thakkar K; Billa G; Rane J; Chudasama H; Goswami S; Shah R Expert Rev Neurother; 2015; 15(12):1373-5. PubMed ID: 26566191 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]